Omnicell Shares Rise on Revised Guidance Following Reduced Tariffs

Dow Jones
2025/05/22
 

By Denny Jacob

 

Omnicell shares rose 5.8% after the company updated its guidance following a temporary reduction in tariffs on China.

Shares were trading around $28.93. The stock is down around 35% on the year.

The healthcare technology company, which automates medication management for hospitals and pharmacies, said it now expects adjusted earnings per-share in the range of 24 cents and 34 cents in the second quarter. It previously forecast adjusted earnings per-share between 19 cents and 32 cents.

For 2025, adjusted earnings are forecast to come in between $1.30 a share and $1.65 a share. It previously forecast adjusted earnings per-share between $1 and $1.65.

Omnicell also disclosed its board approved a new $75 million stock repurchase program, adding to the buyback program approved in 2016 allowing for the repurchase of up to $50 million of the company's common stock.

Chief Executive Randall Lipps said the Trump administration's recent reduction in tariffs on China compelled the company to update its guidance to reflect "the expected diminished impact on our supply chain and anticipated improved profitability."

 

Write to Denny Jacob at denny.jacob@wsj.com

 

(END) Dow Jones Newswires

May 22, 2025 11:17 ET (15:17 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10